Preface

Oncology 2014;87(suppl 1):1–6
DOI: 10.1159/000368140

Breakthroughs in the Management of Hepatocellular Carcinoma: Celebrating 50 Years of the Liver Cancer Study Group of Japan

Masatoshi Kudo

Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

The 50th Liver Cancer Study Group of Japan (LCSGJ) Congress (Congress President: Prof. Masatoshi Kudo) was held in Kyoto, Japan, on June 5–6, 2014. The LCSGJ is an academic society which was founded in 1967 by Dr. Ichio Honjo, Professor of the Department of Surgery at Kyoto University. On March 7, 1949, while working at Kokura Memorial Hospital, Prof. Honjo (fig. 1), at the young age of 35, became the first surgeon in the world to successfully perform an anatomical right lobectomy. Although the Japanese journal Shujutsu (Operation) published this breakthrough in 1950 [1], because it was not published in an English language journal until 1955 [2], there was a period in which articles cited the surgical technique performed by Lortat-Jacob [3] as the world’s first anatomical right lobectomy. However, in the global history of liver surgery, Prof. Honjo is now well recognized as the pioneer who successfully completed the procedure first (fig. 2, 3) [4]. Prof. Honjo subsequently founded the LCSGJ and served as its first president in 1967. Largely due to the historical background, the LCSGJ maintained a head office at Kyoto University until 2008, when it moved to its current location, the Department of Gastroenterology and Hepatology at Kinki University (Head Office Representative: Prof. Masatoshi Kudo).

The theme of the 50th LCSGJ Congress was selected as ‘Breakthroughs in the Management of Hepatocellular Carcinoma’, to celebrate the breakthrough made by Prof. Honjo as well as the numerous breakthroughs in treatments for liver cancer made in the intervening 50 years. The congress program was packed with special features:...
two special lectures, one education lecture, one round-table-style commemorative session on the LCSGJ’s history, three symposia, seven panel discussions, nine workshops, six video sessions, six difficult clinical case study sessions, and two consensus meetings (table 1).

In Symposium 1 entitled ‘Basic Aspect, Diagnosis, Treatment, and Prognosis of Early Hepatocellular Carcinoma’, discussions were held on next-generation sequencing analysis and diagnostic imaging for early hepatocellular carcinoma (HCC) [5], diagnosis by Sonazoid-enhanced ultrasonography and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid MRI, issues associated with pathological diagnosis, and the timing of treatment. Symposium 2 provided a forum for discussion in line with the session ‘Treatment Strategies for Advanced and Large Liver Cancer’ and particularly the attempts to

Fig. 2. Extracted sentences from an article published in Archives of Surgery [4]. Dr. Foster clearly states that Prof. Honjo performed the world’s first anatomic right hepatectomy in Japan in 1949.

Fig. 3. Extracted sentences from an article published in Archives of Surgery [4]. Dr. Foster clearly states that Prof. Honjo performed the world’s first anatomic right hepatectomy in Japan in 1949.
combine surgery and chemotherapy to treat vascular invasion, bile duct invasion, and large liver cancer. In Symposium 3, the heterogeneity of intermediate stage HCC, the attempt to subgroup heterogeneous intermediate stage HCC, the definition of transarterial chemomobilization (TACE) failure/refractoriness, and the treatment options for TACE failure/refractoriness cases were discussed under the title 'Treatment Strategies, Efficacy, and Prognosis of Intermediate Stage Liver Cancer'.

Latest diagnostic imaging modalities [6–9] were introduced in Panel Discussion 1, entitled 'Innovation in Diagnostic Imaging for Liver Cancer', while basic research approaches using, for example, oncogenes and methylation were discussed in Panel Discussion 2 on 'Future Prospects in Liver Cancer Treatment Based on Genome/Epigenome Data'. In Panel Discussion 3 on 'Future Perspectives on Molecular Targeted Therapy for Liver Cancer', discussions centered around the application of molecular targeted therapy, for which sorafenib is currently the only approved drug, the combination of sorafenib with conventional locoregional treatments [10–18], and other emerging targeted agents. In Panel Discussion 4, entitled 'Current Situation and Ongoing Challenges in Liver Transplantation for Patients with Hepatocellular Carcinoma', current issues associated with liver transplantation were addressed, while in Panel Discussion 5, 'Diagnosis and Pathology of Cystic Liver Tumor', new concepts such as intraductal papillary neoplasm of the intrahepatic bile duct and mucinous cystic neoplasm were reviewed. In Panel Discussion 6, pathological features were debated under the theme 'Pathology and Diagnosis of Combined Hepatocellular and Cholangiocellular Carcinoma'. Lastly, in Panel Discussion 7 on 'Various Issues Associated with Hepatocellular Adenoma and Focal Nodular Hyperplasia', the subgroups of hepatocellular adenomas, which have been attracting attention in recent years, and the imaging findings of focal nodular hyperplasia were reviewed.

Nine workshops were held at the congress. In Workshop 1 on 'Treatment for Child-Pugh C Liver Cancer', it was verified that locoregional therapy confers survival benefit to a specific subgroup of liver cancer patients with Child-Pugh C liver function. The discussions in Workshop 2 entitled 'Treatment Strategies for Recurrent Liver Cancer after Liver Transplantation' focused on recurrence, the most serious problem caused by liver transplantation [19–23]. In Workshop 3, the mechanism and clinical approach to nonalcoholic steatohepatitis (NASH)-induced liver cancer were discussed under the theme of 'Basic and Clinical Aspects of NASH-Induced Liver Cancer: Including Diagnostic Criteria' [24]. Workshop 4 on 'Long-term Survival Cases (≥3 Years) of Advanced Hepatocellular Carcinoma after the Initiation of Molecular Targeted Therapy' focused on the characteristics of long-term survival cases after treatment with sorafenib. In Workshop 5 on 'Treatment Strategy for Intrahepatic Cholangiocarcinoma', surgical outcome of intrahepatic cholangiocarcinoma and the
characteristics of recurrence were discussed with a focus on hepatectomy. Workshop 6 focused on ‘Radiation Therapy for Hepatocellular Carcinoma’, and the participants discussed treatment directed solely at vascular invasion or the main lesion of HCC itself and proton and particle therapy [25, 26]. In addition, under the theme ‘Treatment Strategy for Colorectal Liver Metastasis’ in Workshop 7, the participants engaged in an active discussion of systemic chemotherapy, surgical approaches, microwave coagulation therapy, radiofrequency ablation (RFA), or particle therapy as locoregional treatments. The main focus in Workshop 8, entitled ‘Current Situation and Recent Advances in RFA’ was bipolar RFA, and new RFA techniques including fusion image-guided RFA were also discussed [27]. Lastly, in Workshop 9 entitled ‘New Developments in TACE: How to Apply Beads TACE and cTACE Differently’, the participants discussed the differential application of conventional TACE [28] and beads (microsphere) TACE, the latter of which was introduced to Japan in January 2014.

In Video Session 1 entitled ‘State-of-the-Art Contrast-Enhanced Ultrasonography’, the significance of...
this imaging modality for treatment guidance was discussed, as was its value in fusion imaging, in pretreatment diagnosis or treatment was introduced, and in selecting an appropriate treatment approach. Video Session 2 featured ‘Advances in Simulation Imaging (Including 3- and 4-Dimensional Imaging) of Liver Cancer Treatment’ and their applications. Extremely difficult surgical methods in liver resection were introduced and debated in Video Session 3 entitled ‘Resection of Hepatocellular Carcinoma: Highly Technical Surgical Procedures’, while ‘Technological Advances in TACE’ (e.g., beads TACE, balloon occluded-TACE, and FlightPlan) was the theme in Video Session 4. Video Session 5 on ‘The Frontline of Laparoscopic Therapy for Hepatocellular Carcinoma’ covered laparoscope-assisted treatment and robotic surgery with the da Vinci surgical system. Lastly, Video Session 6 entitled ‘Technological Advances in RFA Therapy (Including Fusion Imaging)’ introduced various recent advances in RFA. The six Difficult Clinical Case Study Sessions comprised three sessions on diagnosis and three on treatment, all of which were conducted with a moderator who was either a hepatologist, a surgeon, a pathologist, or a radiologist. In each session, a difficult case in terms of diagnosis or treatment was introduced, and the diagnosis or treatment approach in question was actively debated.

As a special program, a roundtable-style presentation was held under the title ‘Looking Back on the 50-Year History of the Liver Cancer Study Group of Japan’, and eight professors who had led the LCSGJ through the last 50 years introduced the history of the LCSGJ to the younger generation of LCSGJ members. This special program also provided a great opportunity to think about how we should develop the LCSGJ over the next 50 years.

In the Education Lecture, Prof. Kazuto Nishio gave a speech about ‘Biomarkers in Molecular Targeted Therapy for Liver Cancer’, which provided up-to-date information on biomarkers. In addition, Prof. Hidemi Kumai and Prof. Markus Peck presented highly relevant Special Lectures on ‘Full Lifecycle Aquaculture of Bluefin Tuna: 32-Year Trajectory’ and ‘Management of Liver Cancer – Why We Do What We Do in Europe’, respectively.

Two consensus meetings organized by the LCSGJ turned out to be the highlight of the 50th Congress. In Consensus Meeting 1 on ‘A Diagnostic Algorithm for Liver Cancer’, liver cancer experts used a voting system to decide on an updated version of the consensus-based diagnostic algorithm proposed by the Japan Society of Hepatology (JSH) [29]. In Consensus Meeting 2 on ‘Updating the JSH Definition of TACE Failure/Refractoriness’, experts decided to revise the definition [29].

The 50th LCSGJ Congress drew over 1,200 attendees over 2 days and was a great success. In this supplementary issue of Oncology, some of the articles discuss the sessions held at the congress, making it an extremely valuable special issue for readers specializing in liver cancer.

Disclosure Statement
The author declares that no financial or other conflicts of interest exist in relation to the content of this article.

References